Published in J Neurosci on February 26, 2014
Excitatory effects of parvalbumin-expressing interneurons maintain hippocampal epileptiform activity via synchronous afterdischarges. J Neurosci (2014) 1.11
In vivo evaluation of the dentate gate theory in epilepsy. J Physiol (2015) 1.05
Seizure suppression by high frequency optogenetic stimulation using in vitro and in vivo animal models of epilepsy. Brain Stimul (2014) 0.92
Sensitization of neurons in the central nucleus of the amygdala via the decreased GABAergic inhibition contributes to the development of neuropathic pain-related anxiety-like behaviors in rats. Mol Brain (2014) 0.86
Dissecting inhibitory brain circuits with genetically-targeted technologies. Front Neural Circuits (2014) 0.85
Parvalbumin and GAD65 interneuron inhibition in the ventral hippocampus induces distinct behavioral deficits relevant to schizophrenia. J Neurosci (2014) 0.84
Optogenetic tools for modulating and probing the epileptic network. Epilepsy Res (2015) 0.83
Implicating Interneurons: Optogenetic Studies Suggest That Interneurons Are Guilty of Contributing to Epileptiform Activity. Epilepsy Curr (2015) 0.79
GABAergic networks jump-start focal seizures. Epilepsia (2016) 0.79
Optogenetic Approaches for Controlling Seizure Activity. Brain Stimul (2016) 0.78
DREADD in parvalbumin interneurons of the dentate gyrus modulates anxiety, social interaction and memory extinction. Curr Mol Med (2016) 0.78
Optogenetics in preclinical neuroscience and psychiatry research: recent insights and potential applications. Neuropsychiatr Dis Treat (2014) 0.78
Involvement of cortical fast-spiking parvalbumin-positive basket cells in epilepsy. Prog Brain Res (2016) 0.76
Optogenetic study of networks in epilepsy. J Neurosci Res (2016) 0.76
The antiepileptic and ictogenic effects of optogenetic neurostimulation of PV-expressing interneurons. J Neurophysiol (2016) 0.75
Optogenetic activation of VGLUT2-expressing excitatory neurons blocks epileptic seizure-like activity in the mouse entorhinal cortex. Sci Rep (2017) 0.75
NMDA Receptor Expression in the Thalamus of the Stargazer Model of Absence Epilepsy. Sci Rep (2017) 0.75
Interneurons: Role in Maintaining and Restoring Synaptic Plasticity. Front Psychiatry (2016) 0.75
Reliable and Elastic Propagation of Cortical Seizures In Vivo. Cell Rep (2017) 0.75
Neuronal replacement from endogenous precursors in the adult brain after stroke. Nat Med (2002) 10.10
Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats. Brain (2007) 2.49
A general chemical method to regulate protein stability in the mammalian central nervous system. Chem Biol (2010) 2.39
Environment matters: synaptic properties of neurons born in the epileptic adult brain develop to reduce excitability. Neuron (2006) 2.38
Optogenetic control of epileptiform activity. Proc Natl Acad Sci U S A (2009) 2.24
Myeloid and lymphoid contribution to non-haematopoietic lineages through irradiation-induced heterotypic cell fusion. Nat Cell Biol (2008) 2.17
Recombinant adeno-associated viral vector (rAAV) delivery of GDNF provides protection against 6-OHDA lesion in the common marmoset monkey (Callithrix jacchus). Exp Neurol (2003) 1.72
Identification of dopaminergic neurons of nigral and ventral tegmental area subtypes in grafts of fetal ventral mesencephalon based on cell morphology, protein expression, and efferent projections. J Neurosci (2005) 1.67
L-DOPA-induced dyskinesia in the intrastriatal 6-hydroxydopamine model of parkinson's disease: relation to motor and cellular parameters of nigrostriatal function. Neurobiol Dis (2002) 1.54
Cell transplantation in Parkinson's disease: how can we make it work? Trends Neurosci (2005) 1.51
Long-term consequences of human alpha-synuclein overexpression in the primate ventral midbrain. Brain (2007) 1.45
Variability in neuronal expression of dopamine receptors and transporters in the substantia nigra. Mov Disord (2013) 1.44
Serotonin neuron transplants exacerbate L-DOPA-induced dyskinesias in a rat model of Parkinson's disease. J Neurosci (2007) 1.42
GDNF fails to exert neuroprotection in a rat α-synuclein model of Parkinson's disease. Brain (2011) 1.38
Neural stem and progenitor cells retain their potential for proliferation and differentiation into functional neurons despite lower number in aged brain. J Neurosci (2009) 1.37
Inflammation regulates functional integration of neurons born in adult brain. J Neurosci (2008) 1.35
Forebrain acetylcholine regulates adult hippocampal neurogenesis and learning. Neurobiol Aging (2005) 1.31
Wnt5a-treated midbrain neural stem cells improve dopamine cell replacement therapy in parkinsonian mice. J Clin Invest (2008) 1.29
Microglia acquire distinct activation profiles depending on the degree of alpha-synuclein neuropathology in a rAAV based model of Parkinson's disease. PLoS One (2010) 1.29
Feasibility of in vivo 15N MRS detection of hyperpolarized 15N labeled choline in rats. Phys Chem Chem Phys (2010) 1.28
Regulated delivery of glial cell line-derived neurotrophic factor into rat striatum, using a tetracycline-dependent lentiviral vector. Hum Gene Ther (2004) 1.27
Murine models of acute neuronopathic Gaucher disease. Proc Natl Acad Sci U S A (2007) 1.23
Overexpression of glial cell line-derived neurotrophic factor using a lentiviral vector induces time- and dose-dependent downregulation of tyrosine hydroxylase in the intact nigrostriatal dopamine system. J Neurosci (2004) 1.23
Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia. Brain (2008) 1.19
Animal models of Parkinson's disease: limits and relevance to neuroprotection studies. Mov Disord (2012) 1.17
Mutant huntingtin causes metabolic imbalance by disruption of hypothalamic neurocircuits. Cell Metab (2011) 1.14
Differential transduction following basal ganglia administration of distinct pseudotyped AAV capsid serotypes in nonhuman primates. Mol Ther (2009) 1.14
Dose optimization for long-term rAAV-mediated RNA interference in the nigrostriatal projection neurons. Mol Ther (2009) 1.13
Applications of lentiviral vectors for biology and gene therapy of neurological disorders. Curr Gene Ther (2008) 1.12
Proton NMR of (15)N-choline metabolites enhanced by dynamic nuclear polarization. J Am Chem Soc (2009) 1.12
Reconstruction of the nigrostriatal dopamine pathway in the adult mouse brain. Eur J Neurosci (2009) 1.11
Grafted neural stem cells develop into functional pyramidal neurons and integrate into host cortical circuitry. Proc Natl Acad Sci U S A (2002) 1.11
Long-term striatal overexpression of GDNF selectively downregulates tyrosine hydroxylase in the intact nigrostriatal dopamine system. Eur J Neurosci (2003) 1.10
α-Synuclein expression and Nrf2 deficiency cooperate to aggravate protein aggregation, neuronal death and inflammation in early-stage Parkinson's disease. Hum Mol Genet (2012) 1.08
Serotonin-dopamine interaction in the induction and maintenance of L-DOPA-induced dyskinesias. Prog Brain Res (2008) 1.06
Functional integration of grafted neural stem cell-derived dopaminergic neurons monitored by optogenetics in an in vitro Parkinson model. PLoS One (2011) 1.06
Dysregulated dopamine storage increases the vulnerability to α-synuclein in nigral neurons. Neurobiol Dis (2012) 1.05
Isolation and characterization of neural precursor cells from the Sox1-GFP reporter mouse. Eur J Neurosci (2005) 1.02
Seizure suppression by GDNF gene therapy in animal models of epilepsy. Mol Ther (2007) 1.01
Boosting chaperone-mediated autophagy in vivo mitigates α-synuclein-induced neurodegeneration. Brain (2013) 1.01
Ventral tegmental area dopamine neurons are resistant to human mutant alpha-synuclein overexpression. Neurobiol Dis (2006) 1.00
Viral vector-mediated overexpression of α-synuclein as a progressive model of Parkinson's disease. Prog Brain Res (2010) 0.99
Co-expression of C-terminal truncated alpha-synuclein enhances full-length alpha-synuclein-induced pathology. Eur J Neurosci (2010) 0.98
Graft placement and uneven pattern of reinnervation in the striatum is important for development of graft-induced dyskinesia. Neurobiol Dis (2005) 0.98
Functional convergence of dopaminergic and cholinergic input is critical for hippocampus-dependent working memory. J Neurosci (2008) 0.98
Angels and demons: neurotrophic factors and epilepsy. Trends Pharmacol Sci (2006) 0.97
Changes in key hypothalamic neuropeptide populations in Huntington disease revealed by neuropathological analyses. Acta Neuropathol (2010) 0.96
Adeno-associated viral vector-induced overexpression of neuropeptide Y Y2 receptors in the hippocampus suppresses seizures. Brain (2010) 0.95
Involvement of the serotonin system in L-dopa-induced dyskinesias. Parkinsonism Relat Disord (2008) 0.95
GIRK2 expression in dopamine neurons of the substantia nigra and ventral tegmental area. J Comp Neurol (2012) 0.94
Presynaptic dopaminergic compartment determines the susceptibility to L-DOPA-induced dyskinesia in rats. Proc Natl Acad Sci U S A (2010) 0.93
Neuroprotection in the rat Parkinson model by intrastriatal GDNF gene transfer using a lentiviral vector. Neuroreport (2002) 0.93
How might novel technologies such as optogenetics lead to better treatments in epilepsy? Adv Exp Med Biol (2014) 0.91
Early changes in the hypothalamic region in prodromal Huntington disease revealed by MRI analysis. Neurobiol Dis (2010) 0.91
Novel approaches to epilepsy treatment. Epilepsia (2012) 0.91
Ser129D mutant alpha-synuclein induces earlier motor dysfunction while S129A results in distinctive pathology in a rat model of Parkinson's disease. Neurobiol Dis (2013) 0.90
Functional integration of new hippocampal neurons following insults to the adult brain is determined by characteristics of pathological environment. Exp Neurol (2011) 0.90
Decreased expression of brain-derived neurotrophic factor in BDNF(+/-) mice is associated with enhanced recovery of motor performance and increased neuroblast number following experimental stroke. J Neurosci Res (2006) 0.90
In vivo gene delivery for development of mammalian models for Parkinson's disease. Exp Neurol (2007) 0.90
Can overexpression of parkin provide a novel strategy for neuroprotection in Parkinson's disease? Exp Neurol (2008) 0.89
Functional properties and synaptic integration of genetically labelled dopaminergic neurons in intrastriatal grafts. Eur J Neurosci (2005) 0.89
Reversal of dyskinesias in an animal model of Parkinson's disease by continuous L-DOPA delivery using rAAV vectors. Brain (2005) 0.89
An investigation of the problem of two-layered immunohistochemical staining in paraformaldehyde fixed sections. J Neurosci Methods (2006) 0.89
Positron emission tomography imaging demonstrates correlation between behavioral recovery and correction of dopamine neurotransmission after gene therapy. J Neurosci (2009) 0.88
Elevated GDNF levels following viral vector-mediated gene transfer can increase neuronal death after stroke in rats. Neurobiol Dis (2003) 0.88
NPY gene transfer in the hippocampus attenuates synaptic plasticity and learning. Hippocampus (2008) 0.88
The functional impact of the intrastriatal dopamine neuron grafts in parkinsonian rats is reduced with advancing disease. J Neurosci (2007) 0.88
Epilepsy therapy development: technical and methodologic issues in studies with animal models. Epilepsia (2013) 0.88
Magnetic resonance spectroscopic methods for the assessment of metabolic functions in the diseased brain. Curr Top Behav Neurosci (2012) 0.87
Huntington's disease - new perspectives based on neuroendocrine changes in rodent models. Neurodegener Dis (2009) 0.87
Electrophysiological investigations of synaptic connectivity between host and graft neurons. Prog Brain Res (2012) 0.86
Serotonin neuron-dependent and -independent reduction of dyskinesia by 5-HT1A and 5-HT1B receptor agonists in the rat Parkinson model. Exp Neurol (2009) 0.86
Hippocampal NPY gene transfer attenuates seizures without affecting epilepsy-induced impairment of LTP. Exp Neurol (2008) 0.86
Differential suppression of seizures via Y2 and Y5 neuropeptide Y receptors. Neurobiol Dis (2005) 0.86
Lentiviral gene delivery of GDNF into the striatum of R6/2 Huntington mice fails to attenuate behavioral and neuropathological changes. Exp Neurol (2005) 0.85
Restoration of the striatal dopamine synthesis for Parkinson's disease: viral vector-mediated enzyme replacement strategy. Curr Gene Ther (2007) 0.85
Optogenetics reveal delayed afferent synaptogenesis on grafted human-induced pluripotent stem cell-derived neural progenitors. Stem Cells (2014) 0.84
Design of a single AAV vector for coexpression of TH and GCH1 to establish continuous DOPA synthesis in a rat model of Parkinson's disease. Mol Ther (2012) 0.84
Role of serotonin neurons in the induction of levodopa- and graft-induced dyskinesias in Parkinson's disease. Mov Disord (2010) 0.84
Combined gene overexpression of neuropeptide Y and its receptor Y5 in the hippocampus suppresses seizures. Neurobiol Dis (2011) 0.84
Hypothalamic expression of mutant huntingtin contributes to the development of depressive-like behavior in the BAC transgenic mouse model of Huntington's disease. Hum Mol Genet (2013) 0.84
Scientific rationale for the development of gene therapy strategies for Parkinson's disease. Biochim Biophys Acta (2009) 0.83
WONOEP appraisal: optogenetic tools to suppress seizures and explore the mechanisms of epileptogenesis. Epilepsia (2014) 0.83
Dissociation between short-term increased graft survival and long-term functional improvements in Parkinsonian rats overexpressing glial cell line-derived neurotrophic factor. Eur J Neurosci (2004) 0.83
Non-dopaminergic neurons in ventral mesencephalic transplants make widespread axonal connections in the host brain. Exp Neurol (2008) 0.82
Galanin expressed in the excitatory fibers attenuates synaptic strength and generalized seizures in the piriform cortex of mice. Exp Neurol (2006) 0.82
Altered profile of basket cell afferent synapses in hyper-excitable dentate gyrus revealed by optogenetic and two-pathway stimulations. Eur J Neurosci (2012) 0.82
Viral vector mediated overexpression of human alpha-synuclein in the nigrostriatal dopaminergic neurons: a new model for Parkinson's disease. CNS Spectr (2005) 0.82